The influence of thyroglobulin on functional imaging in differentiated thyroid cancer

Nuclear Medicine Communications

Volumn 25, Issue 3, 2004, Pages 239-243

  Menzel, C ^a   Zaplatnikov, K ^a   Diehl, M ^a   Dobert N ^a   Hamscho, N ^a   Grunwald F ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Differentiated thyroid cancer; Iodine 131; PET; RhTSH; Thyroglobulin

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE; IODINE 131; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROXINE;

ADULT; AGED; ARTICLE; BONE METASTASIS; DRUG UPTAKE; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; THYROID CANCER; THYROID GLAND; THYROID SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN; THYROID NEOPLASMS; THYROTROPIN; TOMOGRAPHY, EMISSION-COMPUTED; WHOLE-BODY COUNTING;

EID: 1642310815     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200403000-00005     Document Type: Article

References (19)

1. Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, ‘Onko-PET III’, 21 July and 19 September 2000. Eur J Nucl Med 2001; 28:1707-1723.
2. Grunwald F, Kalicke T, Feine U, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999; 26:1547-1552.
3. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 2002; 87:1490-1498.
4. 131I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999; 84:2291-2302.
5. UICC 1997. In: Wittekind C, Wagner E, eds. Classification of Malignant Tumors, 5th edition. Berlin: Springer; 1997. pp. 52-55.
6. UICC 2002. In: Sobin LH, Witteking C, eds. TNM Classification of Malignant Tumors. New York: Wiley-Liss; 2003. pp. 52-56.
7. Helal BO, Merlet P, Toubert ME, et al. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med 2001; 42:1464-1469.
8. 131I scan. J Nucl Med 2001; 42:71-76.
9. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997; 24:1342-1348.
10. 18F-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 2001; 11:1169-1175.
11. Kizaki M, Dawson MI, Heyman R, et al. Effects of novel retinoid X receptor-selective ligands on myeloid leukemia differentiation and proliferation in vitro. Blood 1996; 87:1977-1984.
12. Grunwald F, Menzel C, Bender H, et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 1998; 39:1903-1906.
13. Simon D, Korber C, Krausch M, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging 2002; 29:775-782.
14. Menzel C, Grunwald F, Schomburg A, et al. ‘High-dose’ radioiodine therapy in advanced differentiated thyroid carcinoma. J Nucl Med 1996; 37:1496-1503.
15. Giovanni V, Arianna LG, Antonio C, et al. The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre. Clin Endocrinol 2002; 56:247-252.
16. Pellegriti G, Scollo C, Giuffrida D, Vigneri R, Squatrito S, Pezzino V. Usefulness of recombinant human thyrotropin in the radiometabolic treatment of selected patients with thyroid cancer. Thyroid 2001; 11:1025-1030.
17. Luster M, Lassmann M, Haenscheid H, Michalowski U, Incerti C, Reiners C. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin Endocrinol Metab 2000; 85:3640-3645.
18. Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid 2002; 12:37-43.
19. Pacini F, Molinaro E, Lippi F, et al. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001; 86:5686-5690.